4DMedical gains U.S. CMS reimbursement for CTVQ
Filed with ASX · · 2 pages · English
Summary by 6ix AI
4DMedical Ltd. announces that the U.S. Centers for Medicare & Medicaid Services has confirmed reimbursement for its CT:VQ technology, which is expected to accelerate market adoption. This development is seen as a significant step towards improving healthcare accessibility and reducing costs for both outpatient and inpatient settings. The company is now positioned to launch CT:VQ commercially across the United States following this confirmation and previous FDA clearance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- 4DMedical receives $6.0m R&D Tax Incentive
- 4DMedical receives FDA clearance for CTVQ
- FY2025 Full year results
- Appendix 4E - Preliminary Final Report
- 4DMedical secures $10mstrategic invest' from Pro Medicus
Later from 4DMedical
- 4DMedical's CT: VQ™ receives FDA 510(k) clearance; First-and-only CT-based VQ technology
- S&P DJI Announces September 2025 Quarterly Rebalance
- 4DX signs agreements with national lung screening sites
- Supplementary announcement - 4DX agreements
- 4DMedical secures $22.6 million via exercise of options
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical